Screener
Harrow HROW Compounding — Cost of Goods Sold
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Harrow in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Harrow’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-022254
| Line item | Branded | Compounding | Consolidated |
|---|---|---|---|
| Product sales, net | $30,631,000 | $13,499,000 | $44,130,000 |
| Other revenues | 73,000 | - | 73,000 |
| Total revenues | 30,704,000 | 13,499,000 | 44,203,000 |
| Cost of sales | 10,954,000 | 6,204,000 | 17,158,000 |
| Gross profit | 19,750,000 | 7,295,000 | 27,045,000 |
| Operating expenses | |||
| Selling, general and administrative | 25,759,000 | 6,742,000 | 32,501,000 |
| Research and development | 5,621,000 | 210,000 | 5,831,000 |
Item 1. Financial Statements (unaudited) Item
FAQ
- What is Harrow's compounding — cost of goods sold?
- Harrow (HROW) reported compounding — cost of goods sold of $6.2M in Q1 2026.
- How has Harrow's compounding — cost of goods sold changed year-over-year?
- Harrow's compounding — cost of goods sold decreased by 15.5% year-over-year, from $7.34M to $6.2M.
- What does compounding — cost of goods sold mean?
- This metric captures the direct costs associated with the production and delivery of compounded pharmaceutical products, including raw materials, labor, and manufacturing overhead. It is a critical measure of production efficiency and supply chain management for the compounding segment. Monitoring these costs is essential for understanding the segment's ability to maintain margins amidst fluctuations in input prices.
Ask your AI about Harrow's compounding — cost of goods sold.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude